Introduction
Enteroviruses (EVs) are single-stranded, positive-sense RNA viruses in the Picornaviridae family. They cause various clinical manifestations, including cutaneous, visceral, and neurological diseases. 1 Human EV can be further classified into four species including human EV A (20 serotypes such as EV71 and coxsackievirus A), human EV B (59 serotypes), human EV C (21 serotypes), and human EV D (4 serotypes). Overall, human EV has more than 100 serotypes. 1,2 For many years, polioviruses were the most important EVs because they caused large outbreaks of paralytic disease before poliovirus vaccines were available. EV71 was first described in California, USA, in 1969. Since then, EV71 has been detected worldwide. 2e5 Globally, two patterns of EV71 epidemic have been reported: small-scale outbreaks with few central nervous system (CNS)-complicated cases and deaths, and large-scale outbreaks with frequent CNScomplicated cases and deaths. The latter pattern occurred in Bulgaria (1975) , in Hungary (1978) , in Malaysia (1997), in Taiwan (1998), in Singapore (2000) , in southern Vietnam (2005, 2007e2009 , and 2011), in Brunei (2006) , in Korea (2009) , and in China (2007e2009). 2, 6 Because EV71 mortality rates are heavily affected by healthcare accessibility and standards, a more relevant clinical definition, such as CNS complication should be also used to quantify disease burden of EV71 infections in prevalent areas.
Although EV71 was first isolated in 1969, a retrospective analysis shows that this virus circulated in The Netherlands as early as 1963. 5 Molecular evolution studies further predicted that EV71 could have emerged in the human population around 1941. 5, 7 Recently, EV71 repeatedly caused life-threatening outbreaks of handefootemouth disease (HFMD) with neurological complications in Asian children. The neurological manifestations progress very quickly and range from aseptic meningitis to acute flaccid paralysis and brainstem encephalitis. 2 Due to its tremendous impact on healthcare systems, development of EV71 vaccines is a national priority in Taiwan and other Asian countries. Several vaccine candidates are being evaluated in humans and some will be licensed in the near future. Epidemiological characteristics are critical to the design of vaccine trials and formulation of vaccination policy when vaccines are licensed. Therefore, this review will focus on epidemiology of EV71 infections in Taiwan.
Clinical spectrum of EV71
According to previous clinical studies conducted in northern Taiwan, symptomatic EV71 infections progress through four stages: HFMD/herpangina (Stage 1), CNS involvement (Stage 2), cardiopulmonary failure (Stage 3), and convalescence (Stage 4). 2 This classification was recently recommended in a World Health Organization (WHO) report. 6 Follow-up studies further demonstrated that EV71 infection can cause long-term sequelae including neurological development and cognitive function. 8 In a prospective hospital-based case-finding study, 21% of 183 EV71 infections in children aged < 18 months of age developed neurological complications such as meningitis and encephalitis. 9 Based on national severe EV surveillance and two cross-sectional serological surveys, Lu et al 10 estimated that 130,617 Taiwanese children aged < 3 years were infected with EV71 infections in 1998 and that 273 (0.21%) of these infected children developed neurological complications. Overall, the prospective hospital-based casefinding study would overestimate the proportion of EV71 infections with neurological complications and the national surveillance data would underestimate the proportion of EV71 infections with neurological complications. In a cohort study conducted from 2006 to 2012 in northern Taiwan, about 100 EV71 primary infections were detected serologically in children younger than 5 years and none of them developed neurological complications (Lee MS et al, unpublished data). Therefore, the proportion of EV71 infections with neurological complications would be between 0.21% and 1%.
Laboratory diagnosis of recent EV71 infections
EVs include over 100 serotypes and usually cause selflimited infections with nonspecific symptoms in children, with the exceptions of polioviruses and EV 71 which frequently cause neurologic complications. Therefore, early detection and serotyping of EVs are critical in clinical management and disease surveillance. Moreover, herpangina and HFMD are major clinical manifestations for EV71 and other EV species A viruses. Therefore, laboratory diagnosis is critical to differentiate EV71 infections from other EVs. There are several methods for laboratory diagnosis of recent EV71 infections, including viruses isolation, molecular methods, and serology ( Table 1 ). The traditional methods for detection and serotyping of EV infections are virus isolation and immunofluorescence assay, which are time-consuming and labor-intensive. 11, 12 Several clinical studies have documented that molecular diagnosis based on polymerase chain reaction saves time and is more sensitive than virus isolation for the detection of EV infections in hospitalized patients, 13e16 but few studies have been conducted on outpatients. Moreover, no study has compared molecular tests and virus isolation/immunofluorescence assay for serotyping of human EVs using clinical specimens. Although these methods have been used to detect EVs in clinical specimens including throat swabs, stool samples, and cerebrospinal fluid, 12e14,16e19 reports elucidating the comparison among the diagnostic approaches are limited.
Molecular tests for the detection of human EVs in clinical specimens usually target highly conserved sites in the 5 0 untranslated region. 20 Due to low virus titers in clinical specimens, several reverse transcription-nested or reverse transcription-seminested polymerase chain reaction have been developed to further increase its sensitivity and specificity.
21e23 However, serotyping of EVs based on 5 0 untranslated region sequences directly amplified from clinical specimens have not been well evaluated. In addition, EV VP1 capsid gene has recently been proposed to be an ideal target for the detection and serotyping of EVs using the consensus degenerate hybrid oligonucleotide primer (CODEHOP). 24 A recent study compared virus isolation and the two molecular tests for detection and serotyping of EVs in clinical samples and found that the VP1 CODEHOP test performed well for detection and serotyping of EVs in clinical specimens and that it could reduce unnecessary hospitalization during EV seasons. 25 Although molecular methods are much more sensitive than the virus isolation for the detection of EV infections, they require skillful manpower and are not suitable for clinics and community hospitals.
There are two serological methods available for laboratory diagnosis of recent EV71 infections, including neutralization assay and enzyme-linked immunosorbent assay (ELISA) immunoglobulin M (IgM). The neutralization assay is the most reliable method but it requires collection of pair sera, which is not feasible for most situations. Several studies have tried to develop ELISA serum IgM methods for rapid diagnosis of EV71 infections but these serum IgM assays all share the drawback of frequent false positive reactions (>20%) in patients infected with other human EVs such as CVA6 and CVA16 (Lee MS et al. unpublished data).
26e28 Serum IgM tests with low false positive reactions are desirable to reduce unnecessary hospitalization during EV seasons.
EV surveillance in Taiwan
A nationwide EV71 epidemic occurred in Taiwan in 1998, which may have caused the largest number of severe cases and deaths in human history. Since then, a national EV surveillance system has been established by Taiwan Centers for Disease Control. The national EV surveillance system includes three components: (1) a sentinel physician network to collect weekly number of HFMD and herpangina, which was recently replaced by the Real-time Outbreak and Disease Surveillance through the National Health Insurance Database; 29, 30 (2) a laboratory network for virus identification by collecting throat swabs from EV-like patients (herpangina and HFMD); and (3) mandatory notification of EV-like severe cases, which collects throat swab, serum, and contact information through an epidemiological investigation. Based on these surveillance data, nationwide EV71 epidemics have occurred cyclically in Taiwan since 1998 (Table 2) . Retrospective studies further found that EV71 epidemics may have occurred in Taiwan in 1980 and 1986. 31, 32 As shown in Table 2 , the first recognized EV71 epidemics occurred in 1998 with 405 severe cases including 78 fatal cases. Nationwide epidemics occurred again in 2000e2001, 2005, 2008 , and 2012 with different predominant genotypes. Overall, clinical spectra of these epidemics were similar although different genotypes predominantly circulated in different years. 32, 33 The laboratory diagnosis methods only employed virus isolation in early years but were revised to include serum IgM and molecular methods later. Therefore, it is not feasible to compare the magnitude of EV71 epidemics based on number of EV71 confirmed severe cases. However, case fatality rates decreased significantly in recent years, which may be related to an early warning of EV71 epidemics and stage-based clinical management.
6,32
Age-specific incidence rates
To design clinical trials of EV71 vaccines, age-specific incidence rates of EV71 infections are required to identify target populations, estimate disease burdens, define endpoints of clinical efficacy, and calculate the sample size for efficacy trials. Age-specific incidence rates of EV71-related severe infections during the 1998 epidemic have been estimated to be 27.3/100,000, 37.1/100,000, 30.0/100,000, and 23.1/100,000 for children aged <6 months, 6e11 months, 12e23 months, and 24e35 months, respectively, which are too low to be a suitable endpoint of efficacy trials. 34 Alternatively, EV71-related mild illness such as herpangina and HFMD could be suitable clinical endpoints. In an infant prospective cohort study initiated in 2006 in Data are presented as n (%). Data source: Taiwan Centers for Disease Control. * Different laboratory methods were used for different years so these data should be interpreted with caution.
y Case fatality rate Z number of deaths/number of severe cases.
northern Taiwan and employing serum neutralization assay to detect EV71 infections, the age-specific incidence rates of EV71 infection during the 2008e2009 epidemic were observed to increase from 1.71/100 personeyears at age 0e6 months infants to 4.09/100 personeyears, 5.74/100 personeyears, and 4.97/100 personeyears in children aged 7e12 months, 13e24 months, and 25e36 months, respectively. In addition, the cumulative incidence rate was 15% by age 36 months, 39% of EV71 infections developed HFMD/ herpangina, and 29% of EV71 infections were asymptomatic in young children. 35 A retrospective serosurvey also found that 37% of seropositive children reported to develop HFMD/herpangina during the 1998 nationwide epidemic in Taiwan. 34 Overall, development of EV71 vaccines should target children age < 6 months, and EV71-related mild illness such as herpangina and HFMD could be used as the clinical endpoints of efficacy trials. 36 
Seroprevalence of serum EV71 neutralizing antibody
In addition to age-specific incidence rates that require time-consuming prospective cohort studies, seroprevalence studies of neutralizing antibody can be readily conducted to estimate cumulative infection rates. Several seroprevalence studies have been completed in Taiwan using sera collected in 1994, 1997, and 1999 (Table 3) . Overall, seropositive rates of EV71 neutralizing antibody in sera collected in 1994 were 39% in 5-year-old children and 57% in 8-year-old children, which indicates that EV71 was prevalent from 1986 to 1994. Seropositive rates of EV71 neutralizing antibody in children aged <3 years in 1997 in Taipei City were about 0% (age 0.5e0.9 years) to 15% (age 3 years), which are much lower than in the same age groups in 1999. In a large-scale cross-sectional serosurvey conducted in 1999 in six areas including two urban (Taipei City and Kaohsiung City) and four rural areas, seropositive rates were higher in the preschool children in rural areas than in the urban areas but similar in school children in both areas, which indicates more intrafamily transmission affecting preschool children occurred in rural areas.
Genetic and antigenic evolutions
According to analysis of VP1 sequences, EV71 was phylogenetically divided into three distinct genogroups: A, B, and C.
1,2 Genogroups B and C can be further divided into genotypes B1eB5 and C1eC5, respectively, and genotype C4 is further classified into subgenotypes C4a and C4b. 36 Recently, genogroups D, E, and F were identified in India. 37 Genogroup A includes the EV71 strain (BrCr-CA-70), which was identified in 1970 in the USA but was not detected again until 2008. In an investigation of the HFMD outbreak in Anhui, China in 2008, five EV71 isolates were identified and they were closely related to genotype A based on analysis of VP1 genes. 38 In 2009, genotype A viruses were further detected in Beijing, Hubei, and Yunan ( Figure 1) . Reasons for the re-emergence of genotype A in China are not clear and should be clarified. By contrast, genotypes B and C continued to circulate around the world after the 1970s and the 1980s, respectively. Recently, retrospective studies have shown that a genotype B0 virus circulated in The Netherlands as early as 1963 and a genotype C0 virus circulated in Japan as early as 1978. 4, 5 Interestingly, genogroup B viruses seemed to evolve through positive selection and only genotype B5 viruses are circulating. By contrast, genogroup C viruses have evolved through neutral selection and multiple genotype C viruses including C2, C4, and C5 are cocirculating globally. 5, 7, 36 Moreover, EVs frequently recombine to generate new genotypes and serotypes, which could only be elucidated by complete genome analysis. Therefore, more efforts are required to generate complete genome data especially early EVs isolated before 1980. 1994 39% for 5 y, 57% for 8 y, 67% for 10e20 y, 58% for 31e50 y Taipei city 10 1997 44% for <6 mo, 0% for 6e11 mo, 5% for 1 y, 16% for 2 y, 15% for 3 y, 38% for 5 y, 47% for 10e20 y Taipei city 10 1999 38% for <6 mo, 15% for 6e11 mo, 20% for 1 y, 22% for 2 y, 21% for 3 y, 29% for 4 y, 29% for 5 y, 33% for 6 y, 51% for 7 y, 47% for 8 y, 64% for 9 y, 63% for 10e20 y, 69% for 21e30 y, 69% for 31e50 y, 77% for >50 y Taipei city 34 1997 36% for <0.5 y, 4% for 0.5e0.9 y, 4% for 1e1.9 y, 22% for 2e2.9 y, 36% for 3e5.9 y, 63% for 6e11 y, 66% for 12e19 y, 57% for 20e29 y Taipei city 34 1999 7% for <0.5 y, 0% for 0.5e0.9 y, 8% for 1e1.9 y, 11% for 2e2.9 y, 34% for 3e5.9 y, 56% for 6e11 y, 54% for 12e19 y, 60% for 20e29 y, 48% for 30e49 Ilan county 34 1999 8% for <0.5 y, 15% for 0.5e0.9 y, 18% for 1e1.9 y, 15% for 2e2.9 y, 49% for 3e5.9 y, 79% for 6e11 y, 74% for 12e19 y, 78% for 20e29 y, 50% for 30e49 y Taoyuan county 34 1999 13% for <0.5 y, 15% for 0.5e0.9 y, 30% for 1e1.9 y, 36% for 2e2.9 y, 49% for 3e5.9 y, 58% for 6e11 y, 60% for 12e19 y, 55% for 20e29 y, 47% for 30e49 y Taichung county 34 1999 12% for <0.5 y, 0% for 0.5e0.9 y, 14% for 1e1.9 y, 30% for 2e2.9 y, 51% for 3e5.9 y, 65% for 6e11 y, 81% for 12e19 y, 73% for 20e29 y, 75% for 30e49 y Kaohsiung city 34 1999 10% for <0.5 y, 3% for 0.5e0.9 y, 5% for 1e1.9 y, 15% for 2e2.9 y, 26% for 3e5.9 y, 57% for 6e11 y, 56% for 12e19 y, 58% for 20e29 y, 72% for 30e49 y Kaohsiung county 34 1999 24% for <0.5 y, 9% for 0.5e0.9 y, 12% for 1e1.9 y, 25% for 2e2.9 y, 40% for 3e5.9 y, 61% for 6e11 y, 68% for 12e19 y, 63% for 20e29 y, 67% for 30e49 y Figure 1 Phylogenetic analysis of VP1 genes of representative EV71 strains. The phylogenetic tree was generated by the neighbor-joining method with 1000 bootstraps based on nucleotide sequence from 2481 to 3278 using genome of EV71 (accession number is U22521) as reference. Only bootstrap values over 70% are shown. Coxsackievirus A16 strain was used as the outlier.
Epidemiology of enterovirus 71 in Taiwan  5 In Taiwan, different predominant genotypes were identified in different epidemics ( Because EV71 genetic variants have been widely identified in Taiwan and globally, it is necessary to examine their antigenic variations, which is critical to the selection of vaccine strains. EV71 has one single serotype as measured by using hyperimmune animal antiserum but antigenic variations have been reported recently in human studies. Using sera collected from young children with a primary infection of genotype B5, two studies detected partial antigenic differences between genogroups B and C but not between viruses in the same genogroup (B5 and B4 viruses). 18, 33 Kung et al 41 did not detect significant antigenic differences between genotypes B4 and C4 viruses using acute-phase sera from EV71 inpatients. A serological survey in healthy Japanese children and adults detected partial antigenic differences between genotype B5 and A viruses but not among different genotypes in genogroups B and C that had previously circulated in Japan. 42 By constructing an antigenic map, however, Huang et al 43 detected antigenic differences between genogroups B and C, and also between B5 and B4 viruses. A recent study found that Taiwanese children infected with genotypes C2, C4, B4, and B5 had lower GMTs (4-fold difference) against genotype A than other genotypes but antigenic variations between genogroups B and C did not have a clear pattern. 44 It is hard to compare different studies that employed different human sera and laboratory procedures, in particular the cell lines used in the neutralization assay. A network to harmonize laboratory procedures including standard sera and viruses is required to make the comparison possible. Moreover, the clinical and epidemiological significance of the observed antigenic variation requires longitudinal serological studies for clarification. In addition, it is not feasible to collect a large amount of serum from children postinfection to measure cross-reactive neutralizing antibody titers against multiple EV71 genotypes. Recently, a rabbit model has been developed to generate antisera for monitoring antigenic variations of EV71, which could be integrated to EV surveillance system (Lee MS, unpublished data).
Conclusions
EV71 is highly contagious and causes life-threatening outbreaks in children in Taiwan and several Asian countries. In the past 10 years, EV71 has caused nationwide epidemics every 3e4 years in Taiwan. Different genotypes dominate in different epidemics but the pattern is not predictable in Taiwan. Case-fatality rates of EV71 infections in recent epidemics seem to decrease significantly in Taiwan due to early warning of EV71 epidemics and stage-based clinical management. Overall, EV71 seems to have evolved rapidly and spread widely in Asia in the past 15 years. The Taiwanese experience on control and prevention of EV71 would be valuable to other countries facing EV71 epidemics.
